Navigation Links
Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
Date:12/14/2010

THE WOODLANDS, Texas, Dec. 14, 2010 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced top-line results from a recently completed Phase 2a study of LX2931 in patients with rheumatoid arthritis (RA).  LX2931 is an orally-delivered, small molecule drug candidate that inhibits sphingosine-1-phosphate (S1P) lyase, an enzyme important for modulating the immune system by controlling S1P levels in lymphoid tissues. The trial was the first test of this new anti-inflammatory mechanism of action in patients and was designed to obtain safety and tolerability information and signals of efficacy.  

Results from the 12-week, randomized, double-blind, placebo-controlled study in 208 patients with RA demonstrated that all three doses tested, 70 mg, 110 mg, and 150 mg given once per day, were well tolerated over the 12-week treatment period.  Taken together, the data also suggested that patients treated with 150 mg once daily of LX2931 showed an improvement in the primary efficacy endpoint, the percentage of patients achieving an American College of Rheumatology 20 (ACR20) response at week 12 (60% versus 49% for placebo).  Patients treated with 70 mg or 110 mg once daily did not indicate improvement in the ACR20 at week 12 (44% and 41% response rates, respectively) relative to placebo. Adverse events for all three LX2931 dose groups were predominantly mild-to-moderate, with frequencies similar to the placebo group.

"We believe the preliminary signal of efficacy and the favorable safety profile observed in this trial supports further study
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)...  CVS Caremark Corporation (NYSE: CVS ) ... 5, 2014, at 8:30 a.m. (EDT) with analysts and ... An audio webcast of the conference call ... of the CVS Caremark website for all interested parties.  ... webcast will be archived and available on the web ...
(Date:7/25/2014)... 25, 2014  Solanbridge Group Inc (OTC: SLNX) is ... interest in Buzznbrewz.com and the Letter of Intent issued ... fully executed Purchase Agreement. Charles R. ... proud to have Mr. David Pecoraro and ... in the private sector and developed a tremendous network ...
(Date:7/25/2014)... , July 25, 2014  AMETEK, Inc. (NYSE: ... Kurtis L. Goos as Vice President and General ... and Packaging (EMIP) Division. "I am pleased ... management and business development experience, especially in the medical ... contributions to the continued growth and success of our ...
Breaking Medicine Technology:Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2
... Actavis Group, the international generic pharmaceuticals company, ... US Food & Drug Administration to market Losartan Potassium ... 25 mg, 50 mg and 100 mg strength.  Losartan ... Iceland. Losartan Potassium Tablets, USP had US ...
... 12 WPI Holdings d/b/a Woodbury Health Products ("Woodbury"), ... announced today that it has completed the acquisition of ... Wilmington, North Carolina and founded in 1993, WMS is ... focused on urological catheters and sterile kits.  With a ...
Cached Medicine Technology:Actavis Receives Approval of Losartan Potassium Tablets, USP in the U.S. 2WPI Holdings Acquires Wilmington Medical Supply Inc. 2
(Date:7/27/2014)... (PRWEB) July 27, 2014 1-Butene is ... has good solvent properties. 1–Butene can be manufactured either ... from the reaction of ethylene. Linear alpha olefin (alkene) ... to manufacture a number of important chemicals such as ... and so on. , The 1-Butene market is extremely ...
(Date:7/27/2014)... Metachromatic leukodystrophy (MLD, also called Arylsulfatase ... is commonly listed in the family of leukodystrophies ... affects the metabolism of sphingolipids. Leukodystrophies affect the ... which acts as an insulator around nerve fibers ... involves cerebroside sulfate accumulation. Metachromatic leukodystrophy, like most ...
(Date:7/27/2014)... -- Couples aren,t more likely to get divorced if ... research finds. The study only looks at trends ... a direct role in affecting whether couples stay together ... against fears that women,s growing educational advantage over men ... lead author of the study, said in an American ...
(Date:7/27/2014)... 2014 Ticket Down is a ... tickets in Miami, FL at the Sun Life Stadium ... is officially underway. In the opening game, Olympiacos from Superleague ... out to an early lead in their group. Six other ... this mini-tournament including Manchester City, Manchester United, AS Roma, Liverpool ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 The ... a special promotion for fall meetings booked at the ... at this Downtown Denver hotel, just steps away from ... Denver’s central business district, and over 100 restaurants and ... their fall 2014 meetings at the HGI Denver will ...
Breaking Medicine News(10 mins):Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 2Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 3Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 2Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 3Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 5Health News:Wives' Higher Education May Not Affect Divorce Rate 2Health News:Guinness International Champions Cup Finals Tickets: Ticket Down Slashes Ticket Prices for International Champions Cup Finals in Miami at Sun Life Stadium 2Health News:Guinness International Champions Cup Finals Tickets: Ticket Down Slashes Ticket Prices for International Champions Cup Finals in Miami at Sun Life Stadium 3Health News:Stonebridge Companies’ Hilton Garden Inn Denver Downtown Announces Fall Meeting Promotion 2
... explain why C-section babies seem more likely to develop ... (HealthDay News) -- Babies who are born vaginally pick ... cesarean section, potentially affecting how their immune systems develop, ... provide more insight into why babies born through cesarean ...
... the polycystic ovary syndrome (PCOS), the most common hormone imbalance ... exposure to the chemical bisphenol A (BPA), found in many ... will be presented Sunday at The Endocrine Society,s 92nd Annual ... a known hormone disrupter, is elevated and associated with higher ...
... ... and revenues. In this Social Media Zuberance webinar we will show you how to avoid becoming ... ... (Founder and CEO of Zuberance) for a free interactive webinar at 11 AM PDT/2 ...
... fish that used to be feminized after chemicals, such as ... Treatment Plant and into Boulder Creek, are taking longer to ... process, according to a new study. The results will be ... San Diego. Although the levels of the chemicals that ...
... ... to Doctors, Physicians and Health Care Providers will monetize their time and streamline their patient ... the next sixty days. , ... (PRWEB) June 21, 2010 -- DocGreet.com is so sure that the services available to ...
... mental disorder affecting one in 100 people worldwide. Most cases ... and hallucinations as a teenager or adult. By that time, ... be difficult to treat. In a paper published recently ... at the University of North Carolina at Chapel Hill and ...
Cached Medicine News:Health News:Delivery Method May Determine the Bacteria Babies Acquire 2Health News:Delivery Method May Determine the Bacteria Babies Acquire 3Health News:Women with polycystic ovary syndrome have higher BPA blood levels 2Health News:Avoid Becoming Social Media Roadkill: Top 5 Ways to Combat Negative Word of Mouth (Free Webinar) 2Health News:Avoid Becoming Social Media Roadkill: Top 5 Ways to Combat Negative Word of Mouth (Free Webinar) 3Health News:Chemicals remaining after wastewater treatment change the gender of fish 2Health News:DocGreet Guarantees More Time and Money to Doctors and Health Care Providers 2Health News:Brain signs of schizophrenia found in babies 2
The Precedent establishes a new generation of revision hip stems....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Calcar replacement stems provide options for revision and trochanteric fractures. Revision hip surgery and trauma often require prosthetic designs that replace proximal medial calcar bone loss....
... contributes to successful outcomes for your ... and technique, the materials you choose ... patients' outcomes, both short-term and long-term. ... Polyethylene. MARATHON Polyethylene is the first ...
Medicine Products: